ProCE Banner Activity

Identification and Management of Adverse Events With TROP2-Targeting ADCs


Download this slideset from a live CCO symposium for nurses to get up to date on key adverse events to watch out for in patients receiving sacituzumab govitecan or datopotamab deruxtecan, including how to identify, monitor for, and manage these toxicities.

Released: April 28, 2023

Begin Activity



Elise Hitron

Elise Hitron, MSN, FNP-C

Nurse Practitioner
Phase I Clinical Trials at Winship Cancer Institute
Atlanta, Georgia

Srigowri Kota

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN

Nurse Practitioner
Department of Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.